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OBJECTIVES: To estimate the morbidity, mortality as well as
direct and indirect costs caused by active cigarette smoking in
Germany in 2003. METHODS: We assessed the number of
deaths and years of potential life lost (YPLL) in Germany in 2003
applying the concept of smoking-attributable fractions and 
the prevalence based approach. Using a top-down approach,
smoking-attributable direct and indirect costs were calculated
from a societal perspective. Direct medical costs were computed
by disease and health care sector. Indirect costs include produc-
tivity losses due to work-loss days, early retirement and prema-
ture deaths which in the base case were valued by the human
capital approach. RESULTS: A total of 121,220 people died
accountable to active cigarette smoking in Germany in 2003.
More than two thirds of all smoking-attributable deaths were
male smokers and YPLL ran up to 1.6 million. Direct medical
costs were €8 billion. Half of these costs (51%) were caused by
smoking-attributable cardiovascular diseases. Neoplasms and
respiratory diseases account for the rest of direct costs in almost
equal shares. Perinatal diseases did not considerably contribute
to this type of costs. Most of direct medical costs occur due to
hospitalisation (48%). Indirect cost due to smoking-attributable
morbidity and premature deaths sum up to €15 billion whereas
the latter account for one third of these costs (34%). Main cost
driver in indirect cost were neoplasms with €6.8 billion followed
by respiratory (€4.0 billion) and cardiovascular diseases (€3.2
billion). Perinatal diseases and burn deaths did not play a sub-
stantial role. CONCLUSIONS: Despite several tobacco tax
increases and other tobacco control measures during the last
decade, smoking still induces a too high burden of disease and
associated costs in Germany.
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Smoking is known as a high risk factor for many types of dis-
eases. It inﬂuences not only to the health conditions but health
care expenditure by those diseases. Economic evaluation of
smoking cessation programs is important to consider efﬁciency
of intervention. OBJECTIVES: To evaluate cost-utility of
smoking cessation therapy and nicotine-replacement therapy
(NRT) in Japan. METHODS: We developed Markov-model to
analyze lifetime costs and utility expressed in QALY gained. To
identify various smoking-related diseases and Markov-transition
probabilities, we organized a committee of expert physicians.
With expert interview, we developed a Markov model. We only
included direct medical cost from the perspective of health care
payer. Efﬁcacy of smoking cessation therapies are derived from
review of RCT. We compared smoking cessation consultation
and NRT with no intervention. We identiﬁed 19 smoking-related
diseases, including 10 cancers based on “Health Risk Appraisal
for Japanese People” developed by Nakamura and Oshima in
2000. One cycle of Markov model was set to 5 years. We
assumed hypothetical cohort who started smoking at the age of
20 and received smoking cessation therapy at the age of 40. We
calculated cost and outcome until the cohort reach to the age of
90. We discounted both cost and outcome at 3% annually.
RESULTS: We found that NRT was more effective and less costly
for those who intended to stop smoking than no intervention.
NRT would save direct medical costs for JPY 272,000(USD
2360) and gains 0.39 QALY compared to doing nothing. If we
do not consider future cost savings from smoking related dis-
eases and, ICER for NRT was JPY 140,000(USD 1217) per
QALY gained. CONCLUSIONS: Smoking cessation therapy and
NRT are cost effective compared to no intervention and will con-
tribute to future cost savings. We will expand this analysis for
various situation (age, sex, etc.) using this model.
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OBJECTIVE: To evaluate comorbidities associated with overac-
tive bladder (OAB). METHODS: A population-based telephone
prevalence survey was conducted among adults ≥18 years of age
in Sweden, Italy, Germany, the UK, and Canada. A nested case-
control analysis was performed on data collected from partici-
pants with OAB (cases; n = 1503) and without OAB (controls;
n = 3076), applying the current International Continence Society
deﬁnitions. Survey participants were asked to report a history of
chronic constipation or diagnoses of the following: asthma, dia-
betes, hypertension (HTN), bladder or prostate cancer, neuro-
logic conditions (multiple sclerosis, stroke, or Parkinson’s
disease), or depression. Respondents noted diuretic use and for
women, parity. Prevalence odds ratios (PORs) and 95% conﬁ-
dence intervals (CIs) were calculated using logistic regression
models for men and women. RESULTS: Several comorbidities
were signiﬁcantly associated with reported OAB. In men, these
included neurologic conditions (POR = 2.7; 95% CI = 1.3–5.7),
depression (POR = 2.5; 95% CI = 1.6–3.7), chronic constipation
(POR = 2.2; 95% CI = 1.1–4.1), and bladder/prostate cancer
(POR = 2.1; 95% CI = 1.1–3.9), after controlling for age, diuretic
use, asthma, HTN, and diabetes. In women, these included neu-
rologic conditions (POR = 2.7; 95% CI = 1.5–4.7), chronic con-
stipation (POR = 2.1; 95% CI = 1.4–3.2), depression (POR =
1.7; 95% CI = 1.3–2.3), diabetes (POR = 1.5; 95% CI = 1.1–2.2),
and HTN (POR = 1.3; 95% CI = 1.1–1.6), after controlling for
age, diuretic use, asthma, and parity. Body mass index and
smoking did not add any precision to the model; the 95% CIs
for these conditions encompassed 1.0. CONCLUSIONS: Several
common chronic health conditions were signiﬁcantly more
prevalent among participants with reported OAB. Chronic con-
stipation, neurologic conditions, and depression were signiﬁ-
cantly associated with OAB in both men and women, even after
adjusting for important covariates such as age, diuretic use, and
other comorbidities. Further research is needed to examine these
associations as potential risk factors for OAB.
